Search results

See details of previously published customer updates from our Health products team. 

The new Micro Computed Tomography (MCT) beamline is the first instrument to become operational as part of the $94 million Project BRIGHT program, which will see the completion of eight new beamlines at ANSTO’s Australian Synchrotron.

ANSTO’s user office in Melbourne offers access to the Australian Synchrotron, a world-class research facility with over 4,000 user visits per year. ANSTO seeks collaboration and partnerships with research organisations, scientific users and commercial users.

This joint initiative at ANSTO has developed a new capability: solid surface radiolabelling to evaluate Auger emitting sources for next-generation targeted therapy.

ANSTO is working with government partners to ensure that radioactivity in drinking water supplied to Aboriginal communities is at levels considered safe for consumption.

International neutron scattering award for retired head of former Bragg Institute, Prof Robert Robinson

Innovative medical device Rhenium-SCT® therapy for non-melanoma skin cancer is now available in Australia

Thirty years of ANSTO's unique capability in monitoring fine particle pollution provides insight on bushfire smoke.

The Imaging and Medical beamline (IMBL) is a flagship beamline of the Australian Synchrotron built with considerable support from the NHMRC. It is one of only a few of its type, and delivers the world’s widest synchrotron x-ray ‘beam’.

Cyclotek and ANSTO have announced the launch of a Joint Venture (JV), to establish Australia’s first GMP (Good Manufacturing Practice) theranostics facility starting in Melbourne, Australia.

Doping with transition metals produced stability in bismuth oxide.

Doping with transition metals produced stability in bismuth oxide.